Clinical Trial Update: Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating CDK4/6 inhibitors as second-line treatment for metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Mansoura University | Conditions: Breast Cancer Stage IV | Phase 3 | Status: UNKNOWN